CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.
about
Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development.CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemiaInotuzumab ozogamicin as novel therapy in lymphomas.Linked-in: design and efficacy of antibody drug conjugates in oncologyNatural glycoconjugates with antitumor activity.Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.
P2860
Q27693252-6202EEA4-7C08-4F4E-B3AF-5D07B870150EQ34165735-621FA340-A6EA-472A-A065-26F74A38F4F0Q34620271-0A3F7E9B-BE9E-4862-9B9A-8C25AF9FEBA7Q37029370-844FA24F-8E6A-40C7-8835-BFDE84041671Q37814157-75BD02C9-8CFB-4E11-A97C-1159FE209BD0Q38002447-0673C3FC-08AF-4A7F-A116-0F17A8F7BA3DQ38109541-337D2524-30A8-419B-AC2D-9EC6FC941BE8Q38379829-AABAD1A5-DF45-4E52-A4D3-CB890F7DA9C2
P2860
CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
CMC-544 (inotuzumab ozogamicin ...... olecules of malignant B-cells.
@en
type
label
CMC-544 (inotuzumab ozogamicin ...... olecules of malignant B-cells.
@en
prefLabel
CMC-544 (inotuzumab ozogamicin ...... olecules of malignant B-cells.
@en
P2093
P2860
P356
P1433
P1476
CMC-544 (inotuzumab ozogamicin ...... olecules of malignant B-cells.
@en
P2093
A Takeshita
N Yamakage
S Nakamura
P2860
P2888
P304
P356
10.1038/LEU.2009.77
P577
2009-04-16T00:00:00Z
P5875
P6179
1014229354